Masoomi Zahra, Nasirian Ali Mohammad, Namazi Mansoor, Zangiabadian Moein, Dayani Abdoreza, Shahidi Mohammad, Saghafi Hossein, Jolfayi Amir Ghaffari
Clinical Research Development Center, Shahid Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran.
Rajaie Cardiovascular Medical and Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Heliyon. 2024 Feb 10;10(4):e25926. doi: 10.1016/j.heliyon.2024.e25926. eCollection 2024 Feb 29.
This study aimed to quantify the incidence of Contrast-induced nephropathy (CIN) in patients undergoing primary percutaneous coronary intervention (PPCI) due to acute ST-elevation myocardial infarction (STEMI).
From April 2019 to March 2022, a prospective, observational study enrolled 213 consecutive STEMI patients referred to a tertiary hospital for PPCI. Participants were divided into tow groups based on the presence or absence of contrast-induced nephropathy. The chi-square test (χ2) and Student's t-test evaluated the data, with logistic regression identifying CIN's independent predictors.
Results: In this study, the incidence of contrast-induced nephropathy was observed at 13.1% (N = 28). Several factors were more prevalent among patients exhibiting contrast-induced nephropathy. These factors encompassed: radial access for coronary angiography over the femoral method (P = 0.021), elevated contrast volume (P = 0.003), smoking (P = 0.009), diabetes (P = 0.04), heart failure (P = 0.049), a history of coronary artery bypass graft (P = 0.006), diminished left ventricular ejection fraction indicating systolic dysfunction (P = 0.012), cardiogenic shock (P = 0.046), increased BUN at the time of admission (P = 0.043), decreased initial GFR (P = 0.004), and prior consumption of medications such as aspirin (P = 0.002), diuretics (P = 0.046), beta blockers (P = 0.04), angiotensin-converting enzyme inhibitors (P = 0.033), angiotensin receptor blockers (P = 0.02). Other relevant conditions included anemia (P = 0.012), leukocytosis (P = 0.011), hypercholesterolemia (P = 0.034), and reduced HDL levels (P = 0.004).Through logistic regression, key predictors for the onset of contrast-induced nephropathy were determined, which included heart failure (OR: 5.52; 95% CI: 1.08-28.24), radial access (OR: 12.71; 95% CI: 1.45-110.9), hypercholesterolemia (OR: 1.02; 95% CI: 1.004-1.04), increased BUN upon admission (OR: 1.11; 95% CI: 1.006-1.24), and leukocytosis (OR: 2.03; 95% CI: 1.18-3.49).
While heart failure, radial access, hypercholesterolemia, elevated BUN at admission, and leukocytosis significantly influenced renal filtration deterioration post-PPCI, it's evident that CIN is multifactorial. Further studies are crucial to elucidate the underlying factors.
本研究旨在量化因急性ST段抬高型心肌梗死(STEMI)接受直接经皮冠状动脉介入治疗(PPCI)的患者中对比剂肾病(CIN)的发生率。
2019年4月至2022年3月,一项前瞻性观察性研究纳入了连续213例因STEMI转诊至三级医院接受PPCI的患者。参与者根据是否发生对比剂肾病分为两组。采用卡方检验(χ2)和学生t检验评估数据,通过逻辑回归确定CIN的独立预测因素。
在本研究中,观察到对比剂肾病的发生率为13.1%(N = 28)。在出现对比剂肾病的患者中,有几个因素更为普遍。这些因素包括:冠状动脉造影采用桡动脉途径而非股动脉途径(P = 0.021)、对比剂用量增加(P = 0.003)、吸烟(P = 0.009)、糖尿病(P = 0.04)、心力衰竭(P = 0.049)、冠状动脉旁路移植术史(P = 0.006)、左心室射血分数降低提示收缩功能障碍(P = 0.012)、心源性休克(P = 0.046)、入院时血尿素氮升高(P = 0.043)、初始肾小球滤过率降低(P = 0.004)以及先前服用阿司匹林(P = 0.002)、利尿剂(P = 0.046)、β受体阻滞剂(P = 0.04)、血管紧张素转换酶抑制剂(P = 0.033)、血管紧张素受体阻滞剂(P = 0.02)等药物。其他相关情况包括贫血(P = 0.012)、白细胞增多(P = 0.011)、高胆固醇血症(P = 0.034)和高密度脂蛋白水平降低(P = 0.004)。通过逻辑回归,确定了对比剂肾病发生的关键预测因素,包括心力衰竭(OR:5.52;95%CI:1.08 - 28.24)、桡动脉途径(OR:12.71;95%CI:1.45 - 110.9)、高胆固醇血症(OR:1.02;95%CI:1.004 - 1.04)、入院时血尿素氮升高(OR:1.11;95%CI:1.006 - 1.24)和白细胞增多(OR:2.03;95%CI:1.18 - 3.49)。
虽然心力衰竭、桡动脉途径、高胆固醇血症、入院时血尿素氮升高和白细胞增多显著影响PPCI后肾滤过功能恶化,但显然CIN是多因素的。进一步研究对于阐明潜在因素至关重要。